Literature DB >> 21841784

Identification of nucleolin as a cellular receptor for human respiratory syncytial virus.

Farnoosh Tayyari1, David Marchant, Theo J Moraes, Wenming Duan, Peter Mastrangelo, Richard G Hegele.   

Abstract

Human respiratory syncytial virus (RSV) causes a large burden of disease worldwide. There is no effective vaccine or therapy, and the use of passive immunoprophylaxis with RSV-specific antibodies is limited to high-risk patients. The cellular receptor (or receptors) required for viral entry and replication has yet to be described; its identification will improve understanding of the pathogenesis of infection and provide a target for the development of novel antiviral interventions. Here we show that RSV interacts with host-cell nucleolin via the viral fusion envelope glycoprotein and binds specifically to nucleolin at the apical cell surface in vitro. We observed decreased RSV infection in vitro in neutralization experiments using nucleolin-specific antibodies before viral inoculation, in competition experiments in which virus was incubated with soluble nucleolin before inoculation of cells, and upon RNA interference (RNAi) to silence cellular nucleolin expression. Transfection of nonpermissive Spodoptera frugiperda Sf9 insect cells with human nucleolin conferred susceptibility to RSV infection. RNAi-mediated knockdown of lung nucleolin was associated with a significant reduction in RSV infection in mice (P = 0.0004), confirming that nucleolin is a functional RSV receptor in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841784     DOI: 10.1038/nm.2444

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  35 in total

1.  Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene.

Authors:  S Techaarpornkul; N Barretto; M E Peeples
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus.

Authors:  P L Collins; G Mottet
Journal:  J Gen Virol       Date:  1991-12       Impact factor: 3.891

3.  Virus entry: two receptors are better than one.

Authors:  F Tufaro
Journal:  Trends Microbiol       Date:  1997-07       Impact factor: 17.079

4.  Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus.

Authors:  Sunee Techaarpornkul; Peter L Collins; Mark E Peeples
Journal:  Virology       Date:  2002-03-15       Impact factor: 3.616

5.  Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.

Authors:  L K Hallak; D Spillmann; P L Collins; M E Peeples
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection.

Authors:  A K Behera; H Matsuse; M Kumar; X Kong; R F Lockey; S S Mohapatra
Journal:  Biochem Biophys Res Commun       Date:  2001-01-12       Impact factor: 3.575

7.  Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells.

Authors:  Rajneesh Malhotra; Malcolm Ward; Helen Bright; Richard Priest; Martyn R Foster; Michael Hurle; Eddie Blair; Michael Bird
Journal:  Microbes Infect       Date:  2003-02       Impact factor: 2.700

8.  The cell surface expressed nucleolin is a glycoprotein that triggers calcium entry into mammalian cells.

Authors:  Marie-Estelle Losfeld; Diala El Khoury; Pascal Mariot; Mathieu Carpentier; Bernard Krust; Jean-Paul Briand; Joël Mazurier; Ara G Hovanessian; Dominique Legrand
Journal:  Exp Cell Res       Date:  2008-11-06       Impact factor: 3.905

9.  Role of glycosaminoglycans for binding and infection of hepatitis B virus.

Authors:  Corinna M Leistner; Stefanie Gruen-Bernhard; Dieter Glebe
Journal:  Cell Microbiol       Date:  2008-01       Impact factor: 3.715

10.  Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model.

Authors:  W Olszewska; G Ispas; C Schnoeller; D Sawant; T Van de Casteele; D Nauwelaers; B Van Kerckhove; D Roymans; M De Meulder; M C Rouan; P Van Remoortere; J F Bonfanti; F Van Velsen; A Koul; M Vanstockem; K Andries; P Sowinski; B Wang; P Openshaw; R Verloes
Journal:  Eur Respir J       Date:  2010-12-09       Impact factor: 16.671

View more
  165 in total

1.  The human respiratory syncytial virus matrix protein is required for maturation of viral filaments.

Authors:  Ruchira Mitra; Pradyumna Baviskar; Rebecca R Duncan-Decocq; Darshna Patel; Antonius G P Oomens
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  Nucleolin interacts with the dengue virus capsid protein and plays a role in formation of infectious virus particles.

Authors:  Corey A Balinsky; Hana Schmeisser; Sundar Ganesan; Kavita Singh; Theodore C Pierson; Kathryn C Zoon
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

3.  The respiratory syncytial virus fusion protein targets to the perimeter of inclusion bodies and facilitates filament formation by a cytoplasmic tail-dependent mechanism.

Authors:  Pradyumna S Baviskar; Anne L Hotard; Martin L Moore; Antonius G P Oomens
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

4.  Human anti-nucleolin recombinant immunoagent for cancer therapy.

Authors:  Dario Palmieri; Timothy Richmond; Claudia Piovan; Tyler Sheetz; Nicola Zanesi; Fulvia Troise; Cindy James; Dorothee Wernicke; Fata Nyei; Timothy J Gordon; Jessica Consiglio; Francesco Salvatore; Vincenzo Coppola; Flavia Pichiorri; Claudia De Lorenzo; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

Review 5.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.

Authors:  Asuncion Mejias; Cristina Garcia-Maurino; Rosa Rodriguez-Fernandez; Mark E Peeples; Octavio Ramilo
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

Review 6.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

7.  Non-typeable Haemophilus influenzae protects human airway epithelial cells from a subsequent respiratory syncytial virus challenge.

Authors:  Stacey M Hartwig; Margaret Ketterer; Michael A Apicella; Steven M Varga
Journal:  Virology       Date:  2016-08-27       Impact factor: 3.616

Review 8.  Molecular mechanisms driving respiratory syncytial virus assembly.

Authors:  Fyza Y Shaikh; James E Crowe
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

Review 9.  Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments.

Authors:  Mark R Ackermann
Journal:  ILAR J       Date:  2014

Review 10.  Hunting Viral Receptors Using Haploid Cells.

Authors:  Sirika Pillay; Jan E Carette
Journal:  Annu Rev Virol       Date:  2015-07-02       Impact factor: 10.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.